Fenbendazole, a well-known antiparasitic drug in veterinary medicine, is increasingly being explored for its potential use in treating parasite infections in humans. Known for its effectiveness against a wide range of parasites—such as roundworms, hookworms, and tapeworms—fenbendazole works by disrupting glucose absorption in parasites, leading to their death and expulsion from the body.

While not officially approved for human use by the FDA or other regulatory agencies, growing anecdotal evidence and early-stage research suggest that fenbendazole may be a viable, low-cost alternative for treating human parasitic infections, especially in areas where access to conventional treatments is limited or unaffordable.

One of the most commonly referenced forms is Fenbendazole 150 mg, which provides a manageable dose that some practitioners are cautiously exploring for off-label use in adults. Fenbendazole 150 mg manufacturer companies have noted increased interest in their products due to this emerging demand, although they emphasize that any human use should be done under professional medical supervision.

Given its affordability, broad-spectrum activity, and low toxicity in animals, fenbendazole could potentially become an important tool in global public health—pending further research and clinical validation for safe human use.